

10/724,857

- 12 -

PC27833 (01459.US1)

REMARKS

Claims 1-29 remain in the application. Only Claim 1 is in independent form.

Claims 1-29 stand rejected 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the enablement requirement. Specifically, it is stated in the Office Action that the "Specification while being enabling for the method for treating said disorders, include, without limitation, chronic and neuropathic pain, migraine therapy, urge, stress and mixed urinary incontinence...these claims does [sic] does not reasonably provide enablement for prevention."

Applicants have amended Claim 1 to remove "prevention" therefrom.

Applicants respectfully submit that the amendment to Claim 1 overcomes the rejection under 35 U.S.C. § 112, first paragraph, and withdrawal of the rejection is respectfully submitted.

Claims 1-29 stand rejected under 35 U.S.C. § 103 as allegedly rendering obvious compounds of Formula IA-IF for the treatment of pain and migraine headache.

In order to expedite the prosecution of the present application, Applicants have amended claim 1 to define a method of treating urge, stress, or mixed urinary incontinence comprising administration of an effective amount of a compound of Formula IA-IF. Applicants respectfully submit that none of the cited references alone or in combination teach or suggest the use of the compounds of Formula IA-IF for treatment of these types of urinary incontinence. It is consequently respectfully submitted that the claims are clearly patentable over the cited prior art combinations, even if the combinations were to be applied, in opposition to applicable law, and reconsideration of the rejections is respectfully requested.

Claims 1-29 stand provisionally rejected under the judicially created doctrine of double patenting over Claims 1-25 of copending Application No. 10/724,856. Applicants respectfully submit that upon allowance of claims in the present application that Applicants will resolve the outstanding double patenting rejection pending in the present application.

10/724,857

- 13 -

PC27833 (01459.US1)

In view of the present amendment and foregoing remarks, reconsideration of the rejection and advancement of the case to issue are respectfully requested.

The Commissioner is authorized to charge any fee or credit any over payment in connection with this communication to our Deposit Account No. 23-0455.

Respectfully submitted,

Date: 1/30/06By: 

David R. Kurlandsky
Registration No. 41,505
Warner-Lambert Company LLC
2800 Plymouth Road
Ann Arbor, MI 48105
Tel.: (734) 622-7304
Fax: (734) 622-2928